Skinmed最新文献

A 24-year-old man with no personal or family history of atopic dermatitis or psoriasis consulted our dermatology department with a desquamating reddish lesion on the left areola and nipple. The lesion, which had developed during the past 4 months, bled occasionally and was treated initially as dermatitis with a combination of topical corticoids and antimicrobials, resulting in partial lessening of the condition. An ultrasound of the skin revealed increased blood flow within the nipple thickening of the dermis. During physical examination, we observed a well-defined desquamating plaque with a slightly shiny surface on the left nipple and areola (Figure 1).

BIMZELX^® (bimekizumab-bkzx) injection, for subcutaneous use, was approved in October 2023 for moderate to severe plaque psoriasis in patients aged ≥18 years. In three phase 3, randomized, double-blind, vehicle, and comparator-controlled studies (Be Vivid, Be Ready, and Be Sure), bimekizumab was investigated for the treatment of plaque psoriasis. The primary efficacy end point was psoriatic area and severity index (PASI) 90 (patients with 90% improvement in PASI from baseline) and investigator's global assessment (IGA) score of 0 (clear skin)-1 (almost clear skin) as well as ≥2-point improvement from baseline at week 16. In the Be Vivid study, patients were randomized into the bimekizumab, placebo, and ustekinumab groups. PASI 90 score was achieved by 85% (273/321) in the bimekizumab group, 5% (4/83) in the placebo group, and 50% (81/163) in the ustekinumab group. IGA 0/1 score was achieved by 84% (270/321) in the bimekizumab group, 5% (4/83) in the placebo group, and 53% (87/163) in the ustekinumab group. In the Be Ready study, patients were randomized into bimekizumab and placebo groups. PASI 90 score was achieved by 91% (317/349) in the bimekizumab group and 1% (1/86) in the placebo group. IGA 0/1 score was achieved by 93% (323/349) in the bimekizumab group and 1% (1/86) in the placebo group. In the Be Sure study, patients were randomized into two bimekizumab groups (receiving different bimekizumab regimens) and one adalimumab group. PASI 90 score was achieved by 86.2% (275/319) in combined bimekizumab groups and 47.2% (75/159) in the adalimumab group. IGA 0/1 score was achieved by 85.3% (272/319) in combined bimekizumab groups and 57.2% (91/159) in the adalimumab group. Bimekizumab was well tolerated with no unexpected safety findings.

Pigmented Bowen's disease (pBD) or pigmented squamous cell cancer in situ is uncommon, accounting for 1.67%-5.5% of Bowen's disease lesions. It resembles pigmented actinic keratosis, seborrheic keratosis, solar lentigo, atypical nevus, or melanoma, and is ruled out through biopsy. Pigmented Bowen's disease typically presents as an asymptomatic, flat or slightly raised, scaly, and well-delineated plaque that primarily affects individuals in their sixties. Risk factors include human papilloma virus infection, arsenic exposure, sun exposure, ionizing radiation, and trauma.

Mucormycosis is an invasive fungal infection caused by fungi of the order Mucorales. During the coronavirus disease 2019 (COVID-19), a rise in the number of COVID-19-associated mucormycosis (CAM) patients was reported globally. Cutaneous mucormycosis is the third most common presentation of mucormycosis. It is classified as primary cutaneous and secondary cutaneous mucormycosis. The secondary form is more common than the primary cutaneous; however, most reports and case series in the literature are that of primary cutaneous mucormycosis. We accounted a case series of eight patients of CAM with secondary cutaneous mucormycosis.

Much like the update in the classification of the acne commensal from Propionibacterium acnes (P. acnes) to Cutibacterium acnes (C. acnes), the treatment of acne has observed advances, augmenting topical and oral medications, including anti-microbial peptides, chemical peels, microencapsulated medications, and probiotics. The traditional paradigm of acne treatment has its limitations, such as skin irritation, photosensitivity, concern over antibiotic resistance, and regimen complexity. Given these challenges, discussing alternative options for acne treatment in detail is important. Light therapy, in particular, is an emerging modality that has transformed the landscape of acne management and thus merits additional discussion (Table 1).

Cabtreo^TM (1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide) or IDP-126 topical gel was approved by the US Food and Drug Administration (FDA) in October 2023 for the treatment of moderate to severe acne vulgaris in patients aged ≥12 years. Its effectiveness and safety were evaluated in two phase 3 trials (Trial 1 and Trial 2). In both trials, subjects were randomized into two groups, one received IDP-126 gel and the other received vehicle gel. The primary efficacy end point was treatment success at week 12, defined as subjects achieving at least a 2-grade reduction from baseline in Evaluator's Global Severity Score (EGGS) and a final score ranging from 0 (clear) to 1 (almost clear) as well as reduced counts of inflammatory and non-inflammatory lesions. In Trial 1 (N = 183), treatment success was achieved in 49.6% (61/122) of subjects in the IDP-126 group versus 24.9% (15/61) of subjects in the vehicle group (P < 0.01). In Trial 2 (N = 180), treatment success was achieved in 50.5% (61/120) of subjects in the IDP-126 group versus 20.5% (12/60) of subjects in the vehicle group (P < 0.01). IDP-126 is therefore recommended to be applied as a thin layer to the affected area once daily.

A 10-year-old healthy, Caucasian girl presented in May 2021 with short and thin scalp hair since birth (Figures 1A-C). She had achieved all of her developmental milestones, and her parents denied any similar family history. She had only two hair cuts in the past, which were performed to trim long hair over the midscalp to have a uniform length. Hair at the front, back, and sides of the scalp were never trimmed. Examination revealed short, dark, and thin hair, varying in length from a few millimeters to 2 cm, over the frontal, parietal, and occipital areas. Longer hair were present over the midscalp, varying in length from 5 cm to 8 cm. The hairpull test was negative, and dermatoscopic examination of short hair demonstrated tapered ends, rather than cut ends. Microscopic examination revealed no hair shaft abnormality, and a trichogram of 50 parietal hair fibers demonstrated an anagen versus telogen ratio of 68:32. No associated skin, dental, or nail abnormalities were discovered.